Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair, reumatology and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

214

total

1,338.943

impact factor

6.257

average impact factor

Group Leader: Ricardo Pujol Borrell

team

zoom

download

During 2018 the scientific production improved and the alliances the groups of “Infection in immunocompromised pediatric patients” and “Genetics Medicine” got closer as high throughput technique applied to diagnosis and research requires to join the expertise of these three groups.

The line on primary immunodeficiencies was strengthen by the assignment by ISCIII of a major project to Dr. Martinez-Gallo. The project aims at improving the diagnosis of the Hemophagocytic Lymphohistiocytosis. This is in addition to the project already in development by Dr Roger Colobran on the same disease and also sponsored by ISCIII.

The line on Immunotolerance and Autoimmune disease carried on its focus on thyroid autoimmunity and more precisely in Graves’ disease. This line is developed in collaboration with surgery, histopathology, endocrinology, pediatrics and clinical chemistry. During 2018 we generated the results that lead to two main research articles being reviewed in 2019.

9

total

30^.846

impact factor

3^.427

average impact factor

SELECTED ARTICLES

Franco-Jarava C, Wang H, Martin-Nalda A, Alvarez SD, Garcia-Prat M, Bodet D, Garcia-Patos V, Plaja A, Rudilla F, Rodriguez-Sureda V, Garcia-Latorre L, Aksentijevich I, Colobran R, Soler-Palacin P
TNFAIP3 haploinsufficiency is the cause of autoinflammatory manifestations in a patient with a deletion of 13Mb on chromosome 6.
Clin Immunol. 2018 Jun; 191: 44-51.
doi: 10.1016/j.clim.2018.03.009..
IF: 3,557
Pujol-Borrell R, Alvarez-Sierra D, Jaraquemada D, Marin-Sanchez A, Colobran R
Central Tolerance Mechanisms to TSHR in Graves’ Disease: Contributions to Understand the Genetic Association.
Horm Metab Res. 2018 Dec;50(12):863-870.
doi: 10.1055/a-0755-7927
IF: 2,56
Soler-Palacin P, Garcia-Prat M, Martin-Nalda A, Franco-Jarava C, Riviere JG, Plaja A, Bezdan D, Bosio M, Martinez-Gallo M, Ossowski S, Colobran R
LRBA Deficiency in a Patient with a Novel Homozygous Mutation Due to Chromosome 4 Segmental Uniparental Isodisomy.
Front Immunol. 2018 Oct 16;9:2397.
doi: 10.3389/fimmu.2018.02397.
FI: 5,511
Dieli-Crimi R, Martinez-Gallo M, Franco-Jarava C, Antolin M, Blasco L, Paramonov I, Semidey ME, Fernandez AA, Molero X, Velasquez J, Martin-Nalda A, Pujol-Borrell R, Colobran R
Th1-skewed profile and excessive production of proinflammatory cytokines in a NFKB1-deficient patient with CVID and severe gastrointestinal manifestations.
Clin Immunol. 2018 Oct;195:49-58.
doi: 10.1016/j.clim.2018.07.015.
FI: 3,557
de Valles-Ibanez G, Esteve-Sole A, Piquer M, Gonzalez-Navarro EA, Hernandez-Rodriguez , Laayouni H, Gonzalez-Roca E, Plaza-Martin AM, Deya-Martinez A, Martin-Nalda A, Martinez-Gallo M, Garcia-Prat M, Del Pino-Molina L, Cusco I, Codina-Sola M, Batlle-Maso L, Solis-Moruno M, Marques-Bonet T, Bosch E, Lopez-Granados E, Arostegui JI, Soler-Palacin P, Colobran R, Yague J, Alsina L, Juan M, Casals F
Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond.
Front Immunol. 2018 May 14;9:636. doi: 10.3389/fimmu.2018.00636.
IF: 5,511

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Ricardo Pujol Borrell

Research Areas